Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155112 | 1.00 | ALDH1A1 (0.47) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL189164 | 0.96 | ALDH1A1 (0.50) | ALDH1A1 | |
| SCHEMBL11867125 | 0.89 | — | — | |
| SCHEMBL188708 | 0.89 | — | — | |
| SCHEMBL868507 | 0.86 | ALDH1A1 (0.42) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL1133217 | 0.86 | ALDH1A1 (0.42) | ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL14218207 | 0.86 | ALDH1A1 (0.57) | ALDH1A1 | |
| SCHEMBL6738460 | 0.86 | ALDH1A1 (0.38) | ALDH1A1 | |
| SCHEMBL23421864 | 0.84 | ALDH1A1 (0.39) | ALDH1A1 | |
| SCHEMBL10846656 | 0.84 | ALDH1A1 (0.39) | ALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10117878-B2 | Ligands for nematode nuclear receptors and uses thereof | BOARD OF REGENTS, UNIVERSITY OF TEXAS SYSTEM (US) | 2018-11-06 | — | — | US | disclosed |
| US-9856219-B2 | Substituted quinoline compounds as S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2018-01-02 | — | — | US | disclosed |
| EP-3247715-A1 | METHODS OF PREVENTING, REDUCING OR TREATING MACULAR DEGENERATION | Inotek Pharmaceuticals Corporation (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9814700-B2 | Pyrrole inhibitors of S-nitrosoglutathione reductase as therapeutic agents | NIVALIS THERAPEUTICS, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9707212-B2 | S-nitrosoglutathione reductase inhibitors | NIVALIS THERAPEUTICS, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-20170049750-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | LAUREL THERAPEUTICS LTD. (CN) | 2017-02-23 | — | — | US | disclosed |
| EP-2897939-B1 | BENZOIMIDAZOLE-CARBOXYLIC ACID AMIDE DERIVATIVES FOR TREATING METABOLIC OR CARDIOVASCULAR DISEASES | SANOFI SA (FR) | 2017-02-01 | — | — | EP | disclosed |
| US-20160367586-A1 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE | INOTEK PHARMACEUTICALS CORPORATION | 2016-12-22 | — | — | US | disclosed |
| EP-2555776-B1 | COMBINATION COMPOSITIONS OF ADENOSINE A1 AGONISTS AND NON-SELECTIVE BETA-ADRENERGIC RECEPTOR BLOCKERS FOR REDUCING INTRAOCULAR PRESSURE | INOTEK PHARMACEUTICALS CORP (US) | 2016-12-07 | — | — | EP | disclosed |
| EP-2555775-B1 | COMBINATION COMPOSITIONS OF ADENOSINE A1 AGONISTS AND CARBONIC ANHYDRASE INHIBITORS FOR REDUCING INTRAOCULAR PRESSURE | INOTEK PHARMACEUTICALS CORP (US) | 2016-12-07 | — | — | EP | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
| US-20050288271-A1 | Arylsulfonamides and uses related thereto | AMGEN INC. (US) | 2005-12-29 | — | — | US | disclosed |
| US-20050282768-A1 | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION | 2005-12-22 | — | — | US | disclosed |
| WO-2005118538-A2 | ARYLSULFONAMIDES AND USES AS HYDROXYSTEROID DEHYDROGENASE | AMGEN, INC. (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | AMGEN SF, LLC (US) | 2005-12-15 | — | — | US | disclosed |
| WO-2005117910-A2 | PURINE DERIVATIVES AS ADENOSINE A1 RECEPTOR AGONISTS AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2005-12-15 | — | — | WO | disclosed |
| US-20050277665-A1 | e.g. 1,1,1-trifluoro-2-[4-(toluene-2-sulfonyl)phenyl]-propan-2-ol; hydroxysteroid dehydrogenases inhibitor; interconversion between cortisone and cortisol in humans; antidiabetic agent; obesity, insulin resistance, non-insulin -dependent diabetes | AMGEN INC. | 2005-12-15 | — | — | US | disclosed |
| WO-2005110980-A2 | ARYL SULFONES AND USES RELATED THERETO | AMGEN, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005063247-A1 | ARYL SULFONAMIDE COMPOUNDS AND USES RELATED THERETO | AMGEN INC. (US) | 2005-07-14 | — | — | WO | disclosed |
| WO-2005051942-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2005-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282768-A1 | Purine derivatives as adenosine A1 receptor agonists and methods of use thereof | ADORA2A, ADORA1, ADORA3 | ALDH1A1 336/4885KDM4E 4441/4885HSD17B10 3776/4885 |
| US-10117878-B2 | Ligands for nematode nuclear receptors and uses thereof | NR4A1, NR0B1, NR1H2 | ALDH1A1 3377/4885KDM4E 2859/4885HSD17B10 1487/4885 |
| US-20170049750-A1 | Novel Pyrrole Inhibitors of S-Nitrosoglutathione Reductase as Therapeutic Agents | GSR, DHFR, GRHPR | ALDH1A1 449/4885KDM4E 1572/4885HSD17B10 197/4885 |
| US-20160367586-A1 | COMBINATION, KIT AND METHOD OF REDUCING INTRAOCULAR PRESSURE | PTGIR, ADORA1, PDE3A | ALDH1A1 994/4885KDM4E 2336/4885HSD17B10 4619/4885 |
| US-20050288271-A1 | Arylsulfonamides and uses related thereto | ARSA, STS, SULT2A1 | ALDH1A1 229/4885KDM4E 2075/4885HSD17B10 203/4885 |
| US-20050277649-A1 | Aryl sulfonamide compounds and uses related thereto | SULT2A1, ARSA, SULT1A1 | ALDH1A1 118/4885KDM4E 1481/4885HSD17B10 350/4885 |
| US-20050277665-A1 | e.g. 1,1,1-trifluoro-2-[4-(toluene-2-sulfonyl)phenyl]-propan-2-ol; hydroxysteroid dehydrogenases inhibitor; interconversion between cortisone and cortisol in humans; antidiabetic agent; obesity, insulin resistance, non-insulin -dependent diabetes | HSD17B1, HSD3B1, HSD11B1 | ALDH1A1 103/4885KDM4E 2921/4885HSD17B10 26/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | ALDH1A1 3055/4885KDM4E 3359/4885HSD17B10 4007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.